Memantine Accord

Memantine Hydrochloride, the active ingredient in Memantine Accord, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, aiming to improve cognition and daily functioning.

GNH USA supplies Memantine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution to meet clinical needs.

Memantine Accord, an NMDA receptor antagonist, is used in the management of Alzheimer’s disease.

Alzheimer’s disease (moderate to severe): helps maintain cognitive function and supports daily activities. Alzheimer’s disease‑related dementia: may slow functional decline in patients with established disease. Behavioral symptoms of Alzheimer’s: can reduce excitotoxic neuronal damage contributing to agitation and aggression.

Memantine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Hypertension - Fatigue

Serious or Rare Side Effects: - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Seizures or increased seizure frequency - Hepatic dysfunction (elevated liver enzymes) - Suicidal thoughts or mood changes - Allergic reactions with swelling of face or throat

When prescribing Memantine Accord, consider the following precautions to ensure safe use.

Renal impairment: assess kidney function and adjust dose if necessary. History of seizures: monitor for increased seizure activity. Cardiovascular disease: use cautiously in patients with hypertension or arrhythmias. Pregnancy and lactation: avoid unless potential benefit justifies the risk. Elderly patients: initiate therapy at the lowest effective dose and titrate slowly. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxic risk. - Ketamine: additive NMDA blockade can lead to excessive CNS depression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce the cognitive benefits of memantine. - Diuretics: can alter plasma concentrations, requiring monitoring. - CNS depressants (e.g., benzodiazepines): may enhance dizziness and sedation.